Cardiovascular Diseases

818 trials 341 recruiting

Filter these 818 trials by phase, country and sponsor.

Open in Search →

COmparison of Bleeding Risk between Rivaroxaban and Apixaban for the treatment of acute venous thromboembolism Ended

2023-504179-26-00 Acute Venous Thromboembolism 6 2024-07-19
A study to learn how asundexian affects the amount of metformin in the blood when healthy participants take them together Ended

2023-509488-26-00 Prevention of ischemic stroke in patients after an acut 3 2024-07-18
A single-dose, open-label study of TX000045 in patients with CpcPH or IpcPH and HFpEF. Ended

2023-508969-32-00 Combined postcapillary and precapillary pulmonary hyper 3 2024-07-08
A Phase IIb Two-Cohort, Randomised, Placebo controlled, Double blind, Multi-centre, Dose-ranging Study of AZD5462 in Stable Patients with Ch… Ended

2023-510148-19-00 Chronic Heart Failure 4 2024-07-03
Phase 2b study to investigate the safety and efficacy of TIN816 in SA-AKI Ended

2023-505903-22-00 Sepsis associated acute kidney injury 4 2024-07-02
Open-label Extension of Vericiguat in Pediatric Participants with Heart Failure due to Left Ventricular Systolic Dysfunction Ended

2023-506210-40-00 Heart Failure due to Systemic Left Ventricular Systolic 5 2024-06-28
A study to learn about the taste of Vericiguat given in liquid form in healthy male participants aged 18 to 45 years Ended

2023-508447-52-00 Heart failure in children 3 2024-06-28
A trial to learn how well REGN7508 works for preventing blood clots after a knee replacement in adult participants Ended

2023-508602-14-00 Thromboembolic disease 4 2024-06-27
Randomized, open-label, single dose, two-period, two-treatment, cross-over bioequivalence study comparing test product Rivaroxaban/Acetylsal… Ended

2024-513665-40-00 not applicable (submitted trial is a bioequivalence in 2 2024-06-25
A trial in healthy volunteers to study safety, tolerability, CS014-levels and effects in the body, after single and repeated doses of CS014,… Ended

2024-510878-24-00 Cardiovascular disease 1 2024-06-24
A randomized, multicenter, open-label trial comparing the effectiveness of Inclisiran to bempedoic acid on LDL cholesterol (LDL-C) lowering … Ended

2024-511076-32-00 Hypercholesterolemia 6 2024-06-21
A randomized, single dose, cross-over bioavailability study comparing the drug-drug interaction between telmisartan tablets, indapamide tabl… Ended

2024-510835-23-00 high blood pressure 3 2024-06-19
MK-7091 Formulations Study in Healthy Adult Participants Ended

2023-510402-40-00 Hypercholesterolemia 3 2024-06-07
Vitamin-K-Antagonist and direct thrombin inhibitor Dabigatran for thrombus resolution in left ventricular thrombus after acute STEMI (ST-ele… Ended

2022-500383-35-00 STEMI (ST elevation myocardial infarction) 4 2024-06-04
A study to learn how safe starting vericiguat at a dose of 5 milligrams is in participants with chronic heart failure with reduced ejection … Ended

2023-507682-25-00 Chronic heart failure with reduced ejection fraction 4 2024-05-13
Effects of single-pill combination of telmisartan/amlodipine and telmisartan/amlodipine/hydrochlorothiazide on 24-hour blood pressure (BP) r… Ended

2023-504812-13-00 Arterial hypertension 11 2024-05-06
Exploratory study to assess the pharmacokinetic interaction of doxepin with adrenaline after a concomitant co-administration using the Anape… Ended

2023-508117-16-00 Anaphylaxis 3 2024-05-03
A clinical research study to learn if baxdrostat works at reducing ambulatory blood pressure and is safe for people with high blood pressure… Ended

2023-507640-36-00 Resistant hypertension (rHTN) defined as blood pressure 5 2024-04-29
MYK-224 in Heart Failure with Preserved Ejection Fraction (HFpEF) Ended

2023-505919-21-00 Heart failure with preserved ejection fraction (HFpEF) 4 2024-04-25
MLS-101-301: A Randomized, Double-Blind, Placebo Controlled, Parallel Arm, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of … Ended

2023-506425-12-00 Uncontrolled and Resistant Hypertension 5 2024-04-17
A Phase 2 Study of CRD-4730 in CPVT Ended

2022-502845-83-00 Catecholaminergic Polymorphic Ventricular Tachycardia ( 4 2024-04-15
Phase 1 study in Staphylococcus aureus endocarditis Ended

2023-505413-25-00 Infectious S. aureus endocarditis 3 2024-04-10
A first human dose study to assess the safety, tolerability, pharmacokinetics and target engagement of single doses of NNC6022-0001 in healt… Ended

2023-505026-34-00 Cardiometabolic diseases 1 2024-03-26
The effect of sertraline on anxiety-depressive symptoms, endothelial dysfunction and biomarkers in heart failure patients with preserved eje… Ended

2024-515061-33-00 Depressive-anxiety states in people with heart failure 5 2024-03-22